Clinical trial
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in…
NCT00006252 · Cancer and Leukemia Group B, Other · Completed
Key facts
| NCT number | NCT00006252 |
|---|---|
| Title | Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma |
| Official title | Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells |
| Lead sponsor | Cancer and Leukemia Group B, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | fludarabine phosphate, Cyclophosphamide, PBSC, G-CSF, Donor lymphocytes |
| Enrollment | 47 |
| Start date | Feb 1, 2001 |
| Primary completion | Jan 1, 2007 |
| Completion | Oct 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 18, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: